Toborzás még nem indult1/2. fázis
A study to investigate the immune response and safety of a vaccine against zoonotic influenza administered into the skin in adults aged 40 to 80 years
A legfontosabb adatok
- Ki végzi
- University Of Antwerp
- Hol
- Belgium, Franciaország, Hollandia és Németország8 helyszín, 4 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1/2. fázis
- Résztvevők
- 258 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2027. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. november 4.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of a diary and attendance to study contacts and study site visits)
- Written or witnessed informed consent obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study-specific procedure
- A male or female aged 40 to 80 years at the time of the first study intervention administration
- Participants who are medically stable in the opinion of the investigator at the time of the study intervention administration. Participants with chronic stable medical conditions with or without specific treatment, such as hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable and without potential influence on the immune response as to the opinion of the investigator
- Female participants of non-childbearing potential (WONCBP) may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and post-menopause*. *A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient
- Female participants of childbearing potential (WOCBP) may be enrolled in the study if the participant meets both of the following criteria: a. has practiced adequate contraception from 1 month prior to study intervention administration and agreed to continue adequate contraception until the end of the study. b. is not pregnant at the day of the study intervention administration, as per the medical anamnesis and pregnancy test
Ki nem vehet részt
- Any SAE attributed to a previous dose of an influenza vaccine
- Prior administration of a H5N1 or any other H5 containing vaccine
- Use of any investigational or non-registered product (drug, vaccine, or invasive medical device) other than the study intervention during the period beginning 28 days before the administration of the study intervention and ending at the completion of the study
- Planned administration of a live attenuated vaccine in the period starting 28 days before the study intervention administration up to 28 days after the administration of the second study intervention (Visit 7)
- Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the completion of the study. a. Up to 3 months prior to the study intervention administration: i. For corticosteroids, this will mean prednisone equivalent ≥ 20 mg/day. Inhaled and topical steroids are allowed. ii. Administration of immunoglobulins and/or any blood products or plasma derivatives. b. Up to 6 months prior to the study intervention administration: long-acting immunemodifying drugs including among other immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies and antitumoral medication
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device)
- Known or suspected history of allergic reaction or hypersensitivity to any component of the study vaccine and/or likely to be exacerbated by egg, chicken protein, ovalbumin, formaldehyde, hydrocortisone, kanamycin, neomycine sulphate, cetyltrimethylammonium bromide (CTAB)
- Recurrent history of uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol
- Serious or unstable chronic illness
- Any history of dementia or any medical condition that moderately or severely impairs cognition
- Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study
- Any medical condition that in the judgment of the investigator would make intramuscular or intradermal injection unsafe
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study
- Is positive for HBsAg, hepatitis C antibodies, or HIV
- Past or current history of autoimmune condition
- History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures
- Any confirmed or suspected immunosuppressive condition, resulting from disease (e.g.,current malignancy, human immunodefiency virus) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory required)
- Body Mass Index < 18.0 or > 30.0 kg/m2
- Presence of a tattoo or local lesions on the study intervention administration sites that would prevent the assessment of the occurrence of local adverse events. At least one upper arm and the contralateral forearm need to be available for study intervention administration
- Participation of any study personnel or their immediate dependents, family, or household members
- Pregnant or lactating female participant
- Female participant planning to become pregnant or planning to discontinue contraceptive precautions
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To demonstrate non-inferiority of humoral immune response to the intradermal H5N8 vaccine compared to the intramuscular H5N8 vaccine.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase I/II multicenter, randomized, double-blind, dose-selecting trial to investigate the immunogenicity, reactogenicity and safety of an intradermally administered zoonotic influenza vaccine targeting H5N8 in different doses compared with intramuscular administration of the same vaccine in adults aged 40 to 80 years
- A regiszteradat frissítve
- 2026. november 4.